OncoGenex's lung cancer drug to enter midstage trial

04/15/2013 | Pharmaceutical Business Review Online

OncoGenex plans to initiate a midstage study to assess the efficacy of its experimental drug OGX-427, in combination with carboplatin and pemetrexed, in extending progression-free survival of previously untreated patients with advanced nonsquamous nonsmall-cell lung cancer. The trial will involve about 155 participants.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations